Background: Although there are many clinical studies in which the beneficial effect of glutamine formulation on mucositis induced by chemo/radiotherapy was evaluated, the results are sometimes conflicting with the report of clinical deterioration. Then, we hypothesized that chemotherapy may increase the incidence of hyperammonemia without comparable change of major parameters of hepatic/renal disorder. Methods: To verify our hypothesis, we examined the increase in blood ammonia level with 1-h intravenous infusion of alanyl-glutamine on day 1-4 after cisplatin (CDDP) administration in rats and assessed the correlation with hepatic/renal parameters. Results: Hepatic parameters (glutamate-oxaloacetic transaminase [GOT] and glutamicpyruvic transaminase [GPT]) with CDDP did not change until day 3 and only GOT increased on day 4. Renal parameters (plasma creatinine, blood urea nitrogen) with CDDP continuously increased up to day 4. Alanyl-glutamine infusion significantly elevated blood ammonia level of CDDP rats with the peak on day 3, although the same dose did not change that of control rats. Conclusion: These results indicates that CDDP enhances the increase in blood ammonia level by glutamine supplementation without correlating with primary parameters for hepatic/renal dysfunction.
Introduction
During chemo/radiotherapy in cancer patients, mucositis in digestive organs, one of primary adverse effects, would be an important dose limiting factors and affects the duration of the therapy and clinical outcomes. Since glutamine is a primary metabolic fuel of enterocytes, many clinical studies to evaluate the beneficial effect of oral/parenteral glutamine supplementation on mucositis associated with chemo/radiotherapy were reported. However, the results were sometimes conflicting [1] [2] [3] [4] [5] [6] [7] [8] . Especially in case of high-dose chemotherapy, deterioration of overall conditions by alanyl-glutamine supplementation is also reported [9] . Since 2 ammonia mole-cules are generated from glutamine metabolism, primary ammonia detoxification system such as metabolism through urea cycle in the liver and excretion by kidney [10, 11] is very important for the safe use of glutamine formulation.
Although Ward et al. [12] reported the dose finding study of glutamine on pediatric oncology patients with chemotherapy, focusing on the elevation of blood ammonia and glutamine level after single oral dose of glutamine, there are very few reports on hyperammonemia relating to chemotherapy.
We hypothesized that a variety of antitumor agents, especially cytotoxic agents, may impair hepatic and renal function even without manifest or correlated changes to major indexes of hepatic and renal dysfunction, leading to a decreased ammonia detoxification capacity, which results in an increased incidence of hyperammonemia by glutamine supplementation. Hyperammonemia causes various systemic disorders especially on nervous system.
The primary adverse effects of platinum-based antitumor agents are reported to be nephrotoxicity, peripheral neuropathy, and digestive symptoms, whereas hepatotoxicity induced by platinum-based chemotherapy does not draw much attention.
In the present study, we examined the increase in blood ammonia level with intravenous alanyl-glutamine infusion, using cisplatin (CDDP)-administered rat model. We also analyzed the correlation of this parameter with the primary hepatic and renal indices which are often used in clinical practice.
Materials and Methods

Animals
Seven-week-old male Wistar Imamichi rats (Sankyo Labo Service Corporation, Inc., Tokyo, Japan), weighing from 190 to 210 g, were maintained at 23 ° C, given standard laboratory chow and water ad libitum, and kept under a 12-h light (7: 00-19: 00)/12-h dark schedule. All animals received humane care in accordance with the Japanese guidelines for animal experimentation (Japanese Association for Laboratory Animal Science). All procedures used in animal experiments were approved by the Animal Ethics Committee of the institution.
Surgical Procedures and Experimental Design
After 6-day acclimation period, the rats were anesthetized with isoflurane (Eskine, Merck, Germany). The neck and interscapular region were shaved and prepared in a sterile manner for catherterization. A silastic catheter was inserted through the right juggler vein and was tunneled subcutaneously to being brought out through the interscapular region. Rats were maintained in individual cage for 6 days to recover. After a post-surgical recovery period, on the starting day of experiment (day 0), the food was withdrawn from 9: 45 to 18: 00. At 14: 00, 4 mg/8 mL/kg CDDP (10 mg/20 mL, Nichi-Iko Pharmaceutical Co., Ltd., Toyama, Japan; CDDP group) or 8 mL/kg saline was administered through the catheter (control group).
Measurement of Plasma GOT, GPT, Creatinine, Blood Urea
Nitrogen, and Blood Ammonia Blood collected from catheter was centrifuged to obtain plasma. The plasma glutamate-oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), and creatinine levels were measured using FUJIDRI-CHEM analyzer (Fuji Film Corporation, Japan). Blood ammonia and blood urea nitrogen (BUN) were measured by FUJIDRI-CHEM analyzer, using whole blood.
Alanyl-Glutamine Load Test
On the designated day after the administration of CDDP or saline, the food was withdrawn at 9: 45. Between 14: 00-15: 00, 10 mL/kg alanyl-glutamine solution was intravenously administered through the catheter for 1 h at the total dose of 1.0-0.7 g/kg. Blood was collected from catheter at the indicated time point and the blood ammonia was measured using FUJIDRI-CHEM analyzer (Fuji Film Corporation, Japan).
Measurement of Plasma Glutamine and Glutamate
Blood collected from catheter was centrifuged to obtain plasma. One hundred microliters of 10% trichloroacetic acid solution was added to 200 μL plasma and mixed thoroughly for deproteinization. After the plasma sample was kept on ice for 10 min, the sample was centrifuged. The supernatant was filtered using an ultrafiltration filter (Ultracel YM-10 regenerated cellulose 10000 MWCO Cat. No. 42407, Merk Millipore, Darmstadt, Germany). The glutamine and glutamate concentration in ultrafiltered sample were measured by an automatic amino acid analyzer (L-8800; Hitachi, Tokyo, Japan). Briefly, amino acids, separated by cation-exchange chromatography, were detected spectrophotometrically after post-column reaction with ninhydrin reagent.
Expression of Data and Statistical Analysis
The results are expressed as the mean ± SEM. The statistical significance of differences was determined by Dunnett test between more than 2 groups and Student t test between 2 groups. The difference between groups was considered significant when p was <0.05.
Results
The Effect of CDDP Administration on Parameters of Hepatic and Renal Function
The plasma GOT and GPT are the most frequently used parameters whose elevation reflects liver cellular injury caused by hepatotoxicity, hepatitis, and so on. In order to examine hepatotoxicity of CDDP, we first measured those parameters on day 1-4 after CDDP adminis-DOI: 10.1159/000485919 tration in CDDP group and compared with control group. The experimental protocol was summarized in Figure 1 .
As shown in Figure 2a , b, both plasma GOT and GPT levels did not significantly change up to day 3, whereas only GOT increased on day 4 without a change of GPT (GOT; 74.7 ± 6.4 vs. 101.0 ± 4.5 U/L [p < 0.05], control vs. CDDP day 4).
In order to examine renal function, plasma creatinine and BUN were monitored. As shown in Figure 2c , d, both parameters continuously increased up to day 4 with the significant difference in the control group on days 3 and 4.
The Effect of CDDP on the Increase in Blood Ammonia Level with Intravenous Alanyl-Glutamine Infusion
The increase of plasma GOT, creatinine, and BUN after CDDP administration suggested the possibility of hepatic and renal toxicity. Although GOT did not significantly increase until day 3, in the previous study, we found that plasma pre-albumin, a rapid turnover protein synthesized in the liver and reflect the hepatic function, decreased on day 2 [13] . From these results, we hypothesized that hepatic detoxification capacity for ammonia might already be deteriorated around day 2, when GOT and GPT has not yet increased. Then, we performed ala- nyl-glutamine load test to monitor the blood ammonia level triggered by intravenous alanyl-glutamine infusion for 1 h (1.0 g/kg) on day 3 in control and CDDP rats. The blood ammonia level was measured just before the start of infusion (-60 min) and 2, 20, 40, 60, 90, 120 min after the completion of infusion. Since this was a preliminary experiment with monitoring at many time points to verify if CDDP makes a significant effect on the increase in blood ammonia level, we examined only 2 animals of each group and showed the result of individual animal in Figure 3a .
In control group, the blood ammonia level did not evidently change in both rats by alanyl-glutamine infusion. In contrast, in CDDP group, the blood ammonia level in both rats increased and the peak level was sustained by 40 min after the completion of the infusion (500-900 μg/dL).
The Daily Change of the Increase in Blood Ammonia with Intravenous Alanyl-Glutamine Infusion and the Base Blood Ammonia Level
In order to examine the daily change in the increase of blood ammonia with intravenous alanyl-glutamine infusion, CDDP rats were subject to alanyl-glutamine load test from days 1 to 4 and compared with control rats. Fig. 3 . The effect of CDDP on the increase in blood ammonia with alanyl-glutamine load test and the base blood ammonia level. The time course of blood ammonia level of an individual animal before and after alanyl-glutamine infusion on day 3 of control and CDDP group (a), the increase in blood ammonia from base level with alanyl-glutamine load test (b) and the base blood ammonia level (c) of control group on day 3 and CDDP group on days 1-4. Intravenous alanyl-glutamine infusion was carried out for 1 h between -60 and 0 min (1.0 g/kg, a; 0.7 g/kg, b). The increase in blood ammonia level (b) was calculated by the deduction of the ammonia level before infusion from that 1 min after the completion of the infusion. The ammonia level before the infusion is regarded as a base ammonia level (c). In (b) and (c), a significant difference from control group is denoted by "asterisk" (* p < 0.05, n = 4).
Color version available online
Obayashi/Kajiwara/Nakamura Since we found that the peak blood ammonia level was sustained by 40 min after the completion of the alanylglutamine infusion by the same test on day 3, the increase of blood ammonia was calculated as a difference of the levels of before and 1 min after the infusion.
As shown in Figure 3b , the increase in blood ammonia level by alanyl-glutamine infusion gradually became higher by day 3, and finally dropped on day 4. In contrast, in the control group, alanyl-glutamine infusion did not raise blood ammonia level (10.7 ± 4.4 vs. 299.5 ± 99.0 ⊿μg/dL [p < 0.05], control vs. CDDP day 3).
The blood ammonia level just before alanyl-glutamine infusion was shown in Figure 3c as a base blood ammonia level. We found that base blood ammonia level did not change by day 3, but increased on day 4 (67.3 ± 4.3 vs. 99.3 ± 5.8 μg/dL [p < 0.05], control vs.
CDDP-day 4).
The Effect of CDDP Administration on Plasma Glutamine and Glutamate Level
Large part of ammonia in the systemic circulation is detoxified to urea through urea cycle in the liver. However, when blood ammonia level increases, such as by urea cycle disorders, blood glutamine level is elevated due to the activation of glutamine synthesis from ammonia and glutamate in extrahepatic tissues, mainly in muscle, to remove toxic ammonia from the circulation [13] [14] [15] . In order to assess the sensitivity of this parameter, we measured plasma glutamine and glutamate level on day 3, when the elevation of blood ammonia by alanyl-glutamine infusion was the highest but the hepatic parameters (e.g., GOT, GPT) and the base blood ammonia level did not change.
As shown in Figure 4a , b, on day 3, plasma glutamine in CDDP group showed significantly higher level than control, whereas plasma glutamate was not different (plasma glutamine; 789.9 ± 52.8 vs. 983.1 ± 8.4 μmol/l [p < 0.05], plasma glutamate; 86.0 ± 3.9 vs. 85.9 ± 3.7 μmol/l, control vs. CDDP group).
Discussion
The aim of this study was to verify our hypothesis that chemotherapy may increase the incidence of hyperammonemia without comparable change of major parameters of hepatic and renal dysfunctions. We examined the increase in blood ammonia level with intravenous alanylglutamine infusion on CDDP-administered rats and assessed the correlation with major parameters of hepatic and renal toxicity.
In the present study, we chose the dose of CDDP at 4 mg/kg. This dose caused atrophy of mucosa in the intestine which peaked on day 3 and then recovered (data not shown). Renal toxicity is reported to be one of primary side effects of CDDP but hepatotoxicity does not draw much attention. Consistently, our present result showed that CDDP significantly elevated plasma creatinine and BUN on day 3-4. Since both creatinine and BUN continuously increased up to day 4 and the increase was quite significant, it is highly possible that CDDP caused renal dysfunction. On the other hand, regarding hepatic parameters, although GOT increased on day 4, it is not clear if this increase is attributable to hepatotoxicity because the elevated level of GOT on day 4 was just about 100 U/L and GPT did not increase, at least, by day 4. GOT is found not only in the liver but also found in the kidney, heart, muscles, and elevated values up to 300 U/L are considered nonspecific [14] .
On the other hand, in the previous study, we found a significant decrease of plasma pre-albumin on day 2 [13] . Pre-albumin is a rapid turnover protein synthesized in the liver and reflects a hepatic function [15] . However, since plasma pre-albumin is excreted by kidney, its plasma level is also affected by renal function. Consistent with this, our previous study showed that plasma pre-albumin significantly dropped on day 2 and gradually increased after day 3 in parallel with the increase of creatinine and BUN. These results suggest that plasma pre-albumin cannot be used as an index of hepatic function when renal dysfunction occurs, but there is a possibility that hepatic function declined on day 2. In the present study, intravenous alanyl-glutamine infusion significantly raised blood ammonia level of CDDP rats without affecting that of control rats, and the increase in blood ammonia of CDDP rats peaked on day 3. This result suggests that CDDP deteriorates ammonia detoxification/excretion capacity, but the change of the increase in blood ammonia by alanyl-glutamine infusion did not correlate with that of typical hepatic and renal parameters, such as GOT, GPT, creatinine, and BUN. More specifically, there was no significant increase in GOT and GPT on day 3 when the increase in blood ammonia by alanyl-glutamine infusion peaked, and creatinine and BUN continuously increased up to day 4.
Alanyl-glutamine infused to the circulation is rapidly degraded into glutamine and alanine [16] . Two and one ammonia are generated through the metabolism of glutamine and alanine, respectively. Ammonia in the circulation is mainly detoxified by periportal hepatocytes through urea cycle [17] . Extra ammonia not used by urea cycle is taken up by perivenous hepatocyte and is detoxified to glutamine by glutamine synthetase (GS) [18] . The significance of the contribution of hepatic ammonia-detoxifying capacity to control blood ammonia level is evident from the fact that 90% of hyperammonemia cases in adults relates to liver disease [19] . When the ammonia detoxification capacity in the liver is not sufficient due to liver dysfunction and leads to the increase of the circulating ammonia, the extra ammonia is eliminated in kidney, brain, and skeletal muscles by being converted to glutamine by GS reaction [20] [21] [22] .The main glutamine producer in the body is the skeletal muscle because of its large mass relative to the other GS-containing organs [23] . In kidney, ammonia and urea are excreted through urine.
Considering the results that (1) plasma pre-albumin significantly decreased on day 2 in the previous study, (2) the increase in blood ammonia was significantly alleviated on day 4 when renal failure continues to deteriorate, (3) the increase in blood ammonia occurred within a short time in response to an intravenous infusion of alanyl-glutamine for 1 h, as well as that the contribution of hepatic ammonia detoxification capacity to control blood ammonia level is significant [19] , we assume that liver dysfunction, rather than renal dysfunction, mainly contributes to this short-term hyperammonemia. The primary toxicity criteria for drug-induced liver injury, which are widely used in clinical practice, are plasma GOT, GPT, alkaline phosphatase, γ-glutamyl transferase, and bilirubin. However, our results suggest that even if plasma GOT and GPT are within the normal range, the hepatic capacity to detoxify ammonia in the circulation may be significantly deteriorated, leading to hyperammonemia when glutamine formulation is administered.
In addition to a lack of correlation between the increase in blood ammonia with intravenous alanyl-glutamine infusion and the major parameters of hepatic and renal disorder, it should be noted that base blood ammonia level also did not correlate with the increase in blood ammonia with alanyl-glutamine infusion. The base blood ammonia level of CDDP group did not change up to day 3 and significantly increased only on day 4. On the other hand, plasma glutamine level in CDDP group significantly increased on day 3, when the increase in blood ammonia with alanyl-glutamine infusion peaked. Since the increase of plasma glutamine is attributable to the increase in the conversion of glutamate to glutamine, mainly in muscle, to eliminate extra ammonia from circulation when circulating ammonia level increases, it is reasonable that the elevation of plasma glutamine precedes that of base blood ammonia. From these results, it is speculated that compared with base blood ammonia level, plasma glutamine may be more sensitive parameter which reflects deterioration of ammonia detoxification/excretion capacity at earlier timing than base ammonia. The reason why base blood ammonia continued to increase up to day 4 when the increase in blood ammonia by alanyl-glutamine infusion began to decline may be that base blood ammonia is affected not only by hepatic ammonia detoxification capacity but also by renal excretion capacity for ammonia.
Taken together, the present study demonstrates that CDDP enhances the increase in blood ammonia level with intravenous alanyl-glutamine infusion without a significant change of major hepatic parameters such as GOT, GPT, and base blood ammonia level. Major renal parameters such as creatinine and BUN also does not correlate with the increase in blood ammonia with alanylglutamine infusion. These results indicate that it is important to evaluate the tolerance to glutamine in patients DOI: 10.1159/000485919 with chemotherapy by an appropriate method even when the primary clinical hepatic parameters are within the normal range.
